Resected oropharyngeal cancer: “no benefit” from intensified adjuvant therapy

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Adjuvant chemoradiotherapy (CRT) and boost doses of postoperative radiotherapy (B-PORT) are not associated with improved overall survival of patients with oropharyngeal squamous cell carcinoma (OPSCC) treated with primary surgery.

Key results

  • CRT (HR, 1.27; 95% CI, 0.70-2.30) an...